
Now loading...
JM Financial has recommended buying Dr Reddy’s Laboratories shares with a target price of Rs 1,737. The current price is Rs 1,325. The company reported a consolidated total income of Rs 8,345.70 crore in the latest quarter, a 5.87% increase from the previous quarter. They expect gRevlimid sales to reach $150 million in the third quarter of 2024.
Now loading...